The bidding for MedImmune Inc. can now begin in earnest. The Gaithersburg, Md.-based company, apparently bowing to pressure from disgruntled shareholders, said it was exploring the option of selling the company. Opening bids likely would start at more than $10 billion, following the 15.3 percent gain in the stock's price Thursday. (BioWorld Today)
The bidding for MedImmune Inc. can now begin in earnest. The Gaithersburg, Md.-based company, apparently bowing to pressure from disgruntled shareholders, said it was exploring the option of selling the company. Opening bids likely would start at more than $10 billion, following the 15.3 percent gain in the stock's price Thursday. (BioWorld Today)
Transgene SA entered its first product-development deal, a collaboration worth up to €218 million (US$293) on its late-stage therapeutic vaccine against human papillomavirus-related diseases. (BioWorld Today)
